Bladder Neoplasm
|
0.090 |
Biomarker
|
disease |
BEFREE |
Here, a mutation panel of six cancer-associated genes (TSC1, FGFR3, TERT, TP53, PIK3CA and ERBB2) and an immunohistochemistry (IHC) panel containing eight bladder cancer (BC) biomarkers (EGFR, RRM1, PD-L1, BRCA1, TUBB3, ERCC, ERCC1, aberrantly glycosylated integrin α3β1 (AG) and CK5/6) were developed.
|
29941343 |
2018 |
Bladder Neoplasm
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, low/negative expression of ERCC1 was associated with higher objective response, median progression-free survival, and median OS in patients with advanced bladder cancer treated with platinum-based chemotherapy.
|
24025563 |
2014 |
Bladder Neoplasm
|
0.090 |
Biomarker
|
disease |
BEFREE |
We aimed to assess the predictive and prognostic values of excision repair cross-complementation 1 (ERCC1) in identifying appropriate patients who may potentially benefit from adjuvant chemotherapy for bladder cancer.
|
22616552 |
2012 |
Bladder Neoplasm
|
0.090 |
Biomarker
|
disease |
BEFREE |
In this study, we examined the correlation between ERCC1 and CRT in vitro and in vivo in bladder cancer.
|
21177407 |
2011 |
Bladder Neoplasm
|
0.090 |
Biomarker
|
disease |
BEFREE |
Prospective studies are warranted to define a role for MDR1 and ERCC1 analysis in individualizing multimodality treatment in locally advanced bladder cancer.
|
20689757 |
2010 |
Bladder Neoplasm
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
ERCC1 haplotypes modify bladder cancer risk: a case-control study.
|
20061190 |
2010 |
Bladder Neoplasm
|
0.090 |
Biomarker
|
disease |
BEFREE |
The results of the study indicate that ERCC1 may predict survival in bladder cancer treated by platinum-based therapy.
|
17229776 |
2007 |
Bladder Neoplasm
|
0.090 |
Biomarker
|
disease |
LHGDN |
The results of the study indicate that ERCC1 may predict survival in bladder cancer treated by platinum-based therapy.
|
17229776 |
2007 |
Bladder Neoplasm
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
We evaluated the influence of common genetic variation in the NER pathway on bladder cancer risk by analyzing 22 single nucleotide polymorphisms (SNP) in seven NER genes (XPC, RAD23B, ERCC1, ERCC2, ERCC4, ERCC5, and ERCC6).
|
16537713 |
2006 |
Bladder Neoplasm
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that polymorphisms and/or haplotypes in XRCC3, XRCC1, and PCNA genes and spanning XPD-ERCC1 region may modulate bladder cancer risk and that some of these effects may preferentially affect current smokers.
|
16284380 |
2005 |